X4 Pharmaceuticals
Roger Hanselmann is a seasoned professional in process chemistry with extensive experience spanning several prestigious organizations. Currently serving as Senior Director of Process Chemistry at X4 Pharmaceuticals since September 2018, Roger previously held the position of Director of Process Research & Development at Akebia Therapeutics from July 2013 to September 2018. Prior roles include Associate Director of Process Chemistry at Rib-X Pharmaceuticals and Senior Research Scientist in Process R&D at DuPont Pharmaceuticals. Roger’s academic background features a Ph.D. in Organic Synthesis from the University of Calgary, complemented by a Postdoctoral Research Associate position at Oregon State University and a Full-Time Teaching Assistant role at Winterthur Polytechnic. Early career experience includes a Laboratory Assistant position at Ciba-Geigy and an apprenticeship with Ciba-Geigy Ltd.
This person is not in the org chart
This person is not in any teams
X4 Pharmaceuticals
3 followers
X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance.